The managing director of IQ products has answered three questions about the role of BiomarkerBay in the field of biomarker research.
"Within BiomarkerBay, the partners add to each other’s values and that of its customers."
Currently I am involved with BiomarkerBay because of my position as managing director of IQ Products. Together with Ymke van der Geld, BiomarkerBay’s CEO, I discuss the possible BiomarkerBay projects related to biomarker assay development and production and regulatory approval. IQ Products performs biomarker research and development in the field of Women’s Health for its own portfolio and offers assay development, improvement and consultancy services to others.
With my background in cell biology and immunology and experience in academic and hospital settings, I, together with my colleagues, can contribute to these external biomarker projects under our ISO13485 certification and in a FDA registered facility.
IQ Products and BiomarkerBay profit from being part of the fastest growing University Campus area of the Netherlands. The expertise concerning biomarkers, discovery and biotechnology is growing too. Working together with BiomarkerBay in the role of business developer and project coordinator and central entity is increasing our presence in the market. This way the partners add to each other’s values and that of its customers.
IQ Products, originally founded by people from the University Medical Center Groningen in 1987, joined BiomarkerBay since the parties involved have complementary capabilities and capacities to facilitate biomarker research. This way we can handle larger projects that require multiple disciplines and in this consortium we have access to a wide range of biomarker services. This way we are supported by a backbone of other (local) partners without competing with each other. We believe this consortium is beneficial to all of the individual partners and creates a one plus one is three situation for both partners and customers.
